Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Commercial Officer, effective as of February 18, 2020. Dr. Yarema has more than 20 years of biopharmaceutical experience during which she has led product strategy and commercialization for therapies at all stages of their life cycle, including those newly entering clinical development, products undergoing multi-region global launches, and maturing products seeking continued growth. She comes to Atara after most recently serving as Amgen’s Vice President & Therapeutic Area Head for Global Product Strategy & Commercial Innovation in Hematology and Oncology. In this role, she had global accountability for all marketed and pipeline products including a portfolio of innovative therapies for var
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyBusiness Wire
- Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceBusiness Wire
ATRA
Earnings
- 8/8/23 - Miss
ATRA
Sec Filings
- 3/18/24 - Form SC
- 3/6/24 - Form 4
- 3/6/24 - Form 4
- ATRA's page on the SEC website